Search the Newsreel

Ceribell Wins FDA Nod for AI Tools on Its Neurology Portal

Ceribell has received FDA 510(k) clearances for two AI enhancements integrated into its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. These tools aim to improve the diagnosis of epilepsy and streamline the interpretation of EEGs by automatically highlighting abnormal brain wave patterns …

CeriBell (CBLL) Stock Premium Rides High Margins Despite Deeper Losses

CeriBell (CBLL) stock saw a 10.4% increase after its Q2 earnings report, driven by headline growth in its high-margin medical device business, despite widened net losses. The company reported revenue of US$28.1m and a net loss of US$19.3m, with investors crediting progress in hospital …

CeriBell (NASDAQ:CBLL) Receives "Buy" Rating from BTIG Research

BTIG Research has reaffirmed its "Buy" rating for CeriBell (NASDAQ:CBLL) and maintained a $28 price target, indicating a potential 45% upside from its current price of $19.30. Despite a wider-than-expected Q2 loss of $0.51 per share, the company's revenue exceeded estimates at $28.1 million. …

Canaccord raises Ceribell stock price target on strong Q2 results

Canaccord increased its price target for Ceribell (NASDAQ:CBLL) to $26 from $25, maintaining a Buy rating, following strong Q2 fiscal 2026 results. The company reported $28.1 million in revenue, a 33% year-over-year increase, and raised its full-year revenue guidance to $114 million-$117 million. Despite …

CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates

CeriBell, Inc. (CBLL) reported a Q2 loss of $0.51 per share, missing the Zacks Consensus Estimate of a $0.45 loss, but exceeded revenue estimates with $28.1 million. Despite underperforming the S&P 500 this year, the company's revenue has topped consensus estimates four times in …

CeriBell Lifts 2026 Revenue Forecast on AI EEG Growth, Reports Wider Quarterly Loss

Ceribell has raised its 2026 revenue forecast to $114-$117 million after a 33% increase in Q2 sales, driven by new hospital accounts and higher utilization. Despite strong growth, the GAAP net loss widened by 41% to $19.3 million due to operating expenses rising faster …

Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review

Ceribell, Inc. announced FDA 510(k) clearance for two new AI algorithm enhancements for its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. These enhancements aim to improve the precision and efficiency of critical-care EEG review by filtering complex background interference and streamlining the …

CeriBell Inc (CBLL) (Q2 2026) Earnings Call Highlights: Revenue Accelerates 33% on Record ...

CeriBell Inc (CBLL) reported a significant revenue increase of 33% year-over-year to $28.1 million in Q2 2026, driven by strong product and subscription growth. Despite widening net losses due to increased operating expenses and IP litigation costs, the company achieved a record gross margin …

CeriBell Q2 revenue rises 33%, raises FY26 guidance to $114M-$117M

Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings

CeriBell (NASDAQ:CBLL) Releases Earnings Results

Ceribell forecasts FY 2026 revenue of $114 million-$117 million

Ceribell has issued a revenue guidance for FY 2026, projecting $114 million-$117 million. The company reported a 33% year-over-year revenue increase in Q2 2026 and a year-to-date gross margin of 90% as of June 30, 2026. Ceribell estimates a U.S. market opportunity of $3.5 …

Earnings call transcript: Ceribell tops revenue growth in Q2 2026, shares rise

Ceribell reported strong Q2 2026 results, with revenue growing 33% year-over-year to $28.1 million, surpassing expectations despite an EPS miss. The medical-device company's shares rose as investors focused on its continued expansion in seizure detection, record gross margins of 92%, and advancement of new …

Ceribell (Nasdaq: CBLL) grows Q2 2026 revenue 33% but posts larger loss

Ceribell Reports Second Quarter 2026 Financial Results

Ceribell announced strong second-quarter 2026 financial results, with total revenue increasing 33% to $28.1 million driven by new account additions and increased utilization. The company also reported significant milestones, including multiple FDA 510(k) clearances for new algorithms and hardware designs, a new credit facility, …

Ceribell (CBLL) lifts 2026 outlook after 33% Q2 revenue growth to $28.1M

Ceribell Receives FDA 510(k) Clearance for New AI-Driven Neurology Portal Enhancements to Improve EEG Interpretation

Ceribell announced it received FDA 510(k) clearance for AI algorithm enhancements to its Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. These new features aim to improve EEG interpretation in critical-care settings by filtering out interference and highlighting abnormalities. The enhancements were developed based …

What To Expect From CeriBell Inc (CBLL) Q2 2026 Earnings

CeriBell Inc (CBLL) is scheduled to release its Q2 2026 earnings on August 10, 2026, with revenue expected at $27.29 million and an estimated earnings per share of -$0.47. Analysts project full-year 2026 revenue to be $113.98 million and earnings per share to be …

CeriBell Inc (CBLL) Earnings Forecast: Future EPS & Revenue Growth Estimates

Ceribell Insider Sold Shares Worth $714,480, According to a Recent SEC Filing

Xingjuan Chao, Director, President, and CEO of Ceribell (CBLL), sold 39,000 shares of the company on August 3, 2026. This transaction amounted to a total value of $714,480. The sale was disclosed in a recent SEC filing.

Ceribell CEO Xingjuan Chao disposes of 39,000 common shares for $714,480

Ceribell President and CEO Xingjuan Chao sold 39,000 common shares for $714,480 at a weighted average of $18.32 per share on August 3. Concurrently, she acquired 25,000 common shares through option exercises priced at $4.70. Following these transactions, her directly held common stock decreased …

Ceribell, Inc. (CBLL) CEO trades 39,000 shares under 10b5-1 plan

Ceribell, Inc.'s President and CEO, Chao Xingjuan, exercised stock options for 25,000 shares at $4.70 per share and subsequently sold 39,000 common shares at a weighted average price of $18.32. These transactions, which generated approximately $714,000 in gross proceeds, were conducted under a Rule …

Analysts’ Top NA Picks: SpaceX (SPCX), Ceribell, Inc. (CBLL)

This article highlights bullish sentiments from analysts for SpaceX (SPCX) and Ceribell, Inc. (CBLL) in the NA sector. Deutsche Bank analyst Edison Yu maintained a Buy rating for SpaceX with a $255.00 price target, while William Blair analyst Brandon Vazquez maintained a Buy rating …

Ceribell Secures CMS New Technology Add-On Payment (NTAP)

Ceribell, a medical technology company, announced it has secured a New Technology Add-on Payment (NTAP) from the U.S. Centers for Medicare & Medicaid Services (CMS) for its Delirium Monitor System. This NTAP, providing up to $2,171 per eligible Medicare patient, aims to broaden access …

Ceribell Receives CMS NTAP for Delirium Monitoring System, Expanding Medicare Access for Point-of-Care EEG Platform

Ceribell, Inc. announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has approved a New Technology Add-on Payment (NTAP) of up to $2,171 for eligible Medicare patients using their FDA-cleared Delirium Monitor System. This system is the first of its kind for …

CeriBell stock rises after securing Medicare payment approval By Investing.com

CeriBell Inc. (NASDAQ:CBLL) shares rose 3% after receiving Medicare payment approval for its Delirium Monitor System. The New Technology Add-on Payment (NTAP) will provide up to $2,171 per eligible Medicare patient, effective October 1, 2026. This approval follows the FDA 510(k) clearance of the …

One Ceribell System Tracks Both Seizures and Delirium at Bedside

Ceribell (Nasdaq: CBLL) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare inpatient case for its Delirium Monitor System, effective October 1, 2026. This system is the …

CeriBell (CBLL) Expected to Announce Quarterly Earnings on Monday

Form 4 CeriBell Inc For: 30 July By Investing.com

This article from Investing.com announces the filing of Form 4 for CeriBell Inc. on July 30. It includes the stock symbol CBLL and notes a 0.28% change. The content primarily serves as a placeholder announcement, offering no further details on the Form 4 itself.

Ceribell, Inc. (CBLL) director receives 16,011 RSUs grant

Ceribell, Inc. director Sharon O'Keefe was granted 16,011 restricted stock units (RSUs) on July 28, 2026. This award, valued at $0.00 per unit, brought her total direct holdings to 16,011 RSUs. The transaction, reported in a Form 4 filing, indicates an equity award rather …

Ceribell (CBLL) director receives 16,011 restricted stock units in equity award

Ceribell, Inc. director Thomas A. West was granted 16,011 restricted stock units (RSUs) of Common Stock on July 28, 2026, as reported in a Form 4 filing. This equity award, valued at $0.00 per share, establishes his direct ownership at 16,011 shares. RSUs are …

Ceribell files Form 3 initial beneficial ownership statement for director Sharon O’Keefe

Ceribell has filed an initial Form 3 beneficial ownership statement for its director, Sharon O’Keefe, dated July 28. This information was generated using AI by Public Technologies (PUBT) from original content published by Ceribell Inc. via the SEC's EDGAR system.

CeriBell (NASDAQ: CBLL) expands board to nine, adds O’Keefe and West

CeriBell, Inc. (NASDAQ: CBLL) has expanded its Board of Directors from seven to nine members, effective July 28, 2026, and rebalanced its director classes for more equal representation. Sharon L. O’Keefe and Thomas A. West were elected as new Class I directors, with O'Keefe …